RxDoctor Payments Data

Tiffany Guerrero

Family · Bronx, NYNPI 1457850893

Payments from drug & device makers

$1,265in general payments, 2019–2025

Across 54 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$522
  • E.r. Squibb & Sons, L.L.C.$168
  • Exact Sciences$138
  • Lilly USA, LLC$113
  • Amarin Pharma, Inc.$63
  • Pfizer$57
  • plus $205 from 7 others

What the payments were for

  • Food & beverage$1,265100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,265 in reported general payments places this provider in the 75th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$14,236
Medicare patients
51
Services billed
227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$92,573
EliquisApixaban64$64,908
JardianceEmpagliflozin51$58,813
FarxigaDapagliflozin Propanediol49$57,715
VascepaIcosapent Ethyl95$48,598
RybelsusSemaglutide28$38,029
JanuviaSitagliptin Phosphate20$29,804
XareltoRivaroxaban20$22,491
SynjardyEmpagliflozin/Metformin Hcl19$19,368
MounjaroTirzepatide11$16,817
TradjentaLinagliptin15$10,926
Breo ElliptaFluticasone/Vilanterol11$5,247
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$4,611
Atorvastatin Calcium351$4,296
Albuterol Sulfate HfaAlbuterol Sulfate88$3,989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$522$130,60192 claims
Boehringer IngelheimJardiance, Synjardy, Tradjenta$25$89,10785 claims
PfizerEliquis$57$64,90864 claims
Lilly USA, LLCMounjaro$113$16,81711 claims
GSKBreo Ellipta$52$5,24711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,883 family providers in New York.

Other family in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →